Related Experiment Video
Updated: Jun 26, 2026
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Effects of diet and gemfibrozil on posttransplant hyperlipidemia in renal transplant recipients
Muzaffer Sapan1, Beste Ozben, Gulsen Yakupoglu
1Department of Nephrology, Akdeniz University, Medical Faculty, Antalya, Turkey.
Insights
The American phase 3 diet and Gemfibrozil effectively manage hyperlipidemia in renal transplant recipients, reducing cardiovascular risks. This study highlights treatment options for posttransplant lipid disorders.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Posttransplant hyperlipidemia is a significant risk factor for cardiovascular disease and graft loss in renal transplant recipients.
- Effective management of hyperlipidemia is crucial to prevent adverse outcomes such as atherosclerosis and glomerular damage.
Purpose of the Study:
- To evaluate the efficacy of the American phase 3 diet and Gemfibrozil in managing hyperlipidemia in renal transplant recipients.
- To identify effective treatment strategies for posttransplant lipid disorders.
Main Methods:
- Lipid profiles were analyzed in 59 renal transplant recipients, with 20 diagnosed with hyperlipidemia (Type IV or Type II).
- A group of 14 patients received the American phase 3 diet for 1 month, while 6 received their regular diet.
- Diet-resistant patients were treated with diet plus placebo, followed by diet plus Gemfibrozil (600 mg twice daily for 2 months).
Main Results:
- The American phase 3 diet normalized lipid profiles in 9 out of 14 patients.
- In diet-resistant patients, Gemfibrozil combined with the diet significantly decreased cholesterol and triglyceride levels.
- Low-density lipoprotein and high-density lipoprotein cholesterol levels showed no significant changes with Gemfibrozil treatment.
Conclusions:
- The American phase 3 diet is effective in controlling hyperlipidemia in a subset of renal transplant recipients.
- Gemfibrozil, in combination with the American phase 3 diet, provides a viable therapeutic option for diet-resistant hyperlipidemia post-transplant.
- These interventions are crucial for mitigating cardiovascular risks associated with posttransplant hyperlipidemia.
Background:
Posttransplant hyperlipidemia increases cardiovascular morbidity and mortality rate in renal transplant recipients. It also leads to graft loss due to atherosclerosis and glomerular damage. It is essential to control hyperlipidemia in renal transplant recipients to prevent these events.
Methods:
In our study, we determined lipid profiles in 59 renal transplant recipients. Twenty of the recipients had hyperlipidemia; 9 had type IV, and 11 had type II hyperlipoproteinemia. Randomly selected 14 of 20 hyperlipidemic patients consisted of the diet group and were treated with American phase 3 diet for 1 month. Randomly selected 6 of the 20 hyperlipidemic patients received their regular diet as the control group. Five diet-resistant patients in the American phase 3 diet group were given diet plus placebo for another 1 month and then they were given diet plus Gemfibrozil (600 mg twice a day) for 2 months.
Results:
Lipid profile was normalized in 9 of the 14 patients on American phase 3 diet. The lipid profile of 5 patients in the American phase 3 diet group did not change significantly after 1-month diet. These 5 diet-resistant patients were given diet plus placebo for another 1 month, and their lipid levels again did not change significantly. Afterward, they were treated with Gemfibrozil (600 mg twice a day) plus American phase 3 diet for 2 months. At the end of this therapy period, their cholesterol level and triglyceride level decreased significantly. No change was observed in low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels.
Conclusions:
We conclude that American phase 3 diet and/or Gemfibrozil are effective in controlling posttransplant hyperlipidemia in renal transplant recipients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
01:26Kidney Transplant II: Surgical Procedure
01:28Kidney Transplant I: Introduction
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow